There were 348 press releases posted in the last 24 hours and 153,676 in the last 365 days.

New Research: Key Drivers of Growth for Ironwood Pharmaceuticals, State Street, CMS Energy, Virtus Investment Partners, Capstone Turbine, and UROGEN PHARMA — Factors of Influence, Major Initiatives and Sustained Production

NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), State Street Corporation (NYSE:STT), CMS Energy Corporation (NYSE:CMS), Virtus Investment Partners, Inc. (NASDAQ:VRTS), Capstone Turbine Corporation (NASDAQ:CPST), and UROGEN PHARMA (NASDAQ:URGN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

/EIN News/ -- Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

IRWD DOWNLOAD: http://Capital-Review.com/register/?so=IRWD
STT DOWNLOAD: http://Capital-Review.com/register/?so=STT
CMS DOWNLOAD: http://Capital-Review.com/register/?so=CMS
VRTS DOWNLOAD: http://Capital-Review.com/register/?so=VRTS
CPST DOWNLOAD: http://Capital-Review.com/register/?so=CPST
URGN DOWNLOAD: http://Capital-Review.com/register/?so=URGN

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), State Street Corporation (NYSE:STT), CMS Energy Corporation (NYSE:CMS), Virtus Investment Partners, Inc. (NASDAQ:VRTS), Capstone Turbine Corporation (NASDAQ:CPST), and UROGEN PHARMA (NASDAQ:URGN) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

IRONWOOD PHARMACEUTICALS, INC. (IRWD) REPORT OVERVIEW

Ironwood Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Ironwood Pharmaceuticals reported revenue of $130.69MM vs $94.21MM (up 38.73%) and analysts estimated basic earnings per share -$0.10 vs $0.10. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Ironwood Pharmaceuticals reported revenue of $346.64MM vs $298.28MM (up 16.21%) and analysts estimated basic earnings per share -$1.85 vs -$0.78. Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.27. The estimated EPS forecast for the next fiscal year is $0.57 and is expected to report on February 12th, 2020.

To read the full Ironwood Pharmaceuticals, Inc. (IRWD) report, download it here: http://Capital-Review.com/register/?so=IRWD

-----------------------------------------

STATE STREET CORPORATION (STT) REPORT OVERVIEW

State Street's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, State Street reported interest income of $982.00MM vs $797.00MM (up 23.21%) and analysts estimated basic earnings per share $1.03 vs $0.90 (up 14.44%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, State Street reported interest income of $3,662.00MM vs $2,908.00MM (up 25.93%) and analysts estimated basic earnings per share $6.48 vs $5.32 (up 21.80%). Analysts expect earnings to be released on April 23rd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $1.62. The estimated EPS forecast for the next fiscal year is $7.51 and is expected to report on January 17th, 2020.

To read the full State Street Corporation (STT) report, download it here: http://Capital-Review.com/register/?so=STT

-----------------------------------------

CMS ENERGY CORPORATION (CMS) REPORT OVERVIEW

CMS Energy's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, CMS Energy reported revenue of $1,829.00MM vs $1,778.00MM (up 2.87%) and analysts estimated basic earnings per share $0.38 vs -$0.01. For the twelve months ended December 31st, 2018 vs December 31st, 2017, CMS Energy reported revenue of $6,873.00MM vs $6,583.00MM (up 4.41%) and analysts estimated basic earnings per share $2.33 vs $1.64 (up 42.07%). Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.86. The estimated EPS forecast for the next fiscal year is $2.68 and is expected to report on January 30th, 2020.

To read the full CMS Energy Corporation (CMS) report, download it here: http://Capital-Review.com/register/?so=CMS

-----------------------------------------

VIRTUS INVESTMENT PARTNERS, INC. (VRTS) REPORT OVERVIEW

Virtus Investment Partners' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Virtus Investment Partners reported revenue of $138.07MM vs $128.02MM (up 7.84%) and basic earnings per share $0.04 vs $0.44 (down 90.91%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Virtus Investment Partners reported revenue of $552.24MM vs $425.61MM (up 29.75%) and analysts estimated basic earnings per share $9.37 vs $4.09 (up 129.10%). Analysts expect earnings to be released on April 26th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $2.59. The estimated EPS forecast for the next fiscal year is $11.67 and is expected to report on February 7th, 2020.

To read the full Virtus Investment Partners, Inc. (VRTS) report, download it here: http://Capital-Review.com/register/?so=VRTS

-----------------------------------------

CAPSTONE TURBINE CORPORATION (CPST) REPORT OVERVIEW

Capstone Turbine's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Capstone Turbine reported revenue of $18.03MM vs $22.76MM (down 20.79%) and analysts estimated basic earnings per share -$0.05 vs -$0.01. For the twelve months ended March 31st, 2018 vs March 31st, 2017, Capstone Turbine reported revenue of $82.84MM vs $77.17MM (up 7.34%) and analysts estimated basic earnings per share -$0.20 vs -$0.79. Analysts expect earnings to be released on June 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.02. The estimated EPS forecast for the next fiscal year is -$0.05 and is expected to report on June 6th, 2019.

To read the full Capstone Turbine Corporation (CPST) report, download it here: http://Capital-Review.com/register/?so=CPST

-----------------------------------------

UROGEN PHARMA (URGN) REPORT OVERVIEW

UROGEN PHARMA's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, UROGEN PHARMA reported revenue of $0.00MM vs $0.33MM and analysts estimated basic earnings per share -$1.50 vs $0.32. For the twelve months ended December 31st, 2018 vs December 31st, 2017, UROGEN PHARMA reported revenue of $1.13MM vs $8.16MM (down 86.17%) and analysts estimated basic earnings per share -$4.80 vs -$2.14. Analysts expect earnings to be released on May 21st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.88. The estimated EPS forecast for the next fiscal year is -$3.66 and is expected to report on February 27th, 2020.

To read the full UROGEN PHARMA (URGN) report, download it here: http://Capital-Review.com/register/?so=URGN

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Morena Zambada, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.